probiotics
On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.
Lonza's capsules ensures targeted intestinal delivery enhancing stability and therapeutic efficacy for LBPs and pharmaceutical applications.
Cmbio announces a strategic partnership with Nimble Science to deliver first in class high-quality, multi-omic data insights from the small intestine.
Its emergence in the respiratory health sector represents a paradigm shift, offering promising avenues for innovation and investment.
Raphaëlle Bourdet-Sicard from Danone Nutricia Research discusses a study which investigates the use of a mixed prebiotic formulation to enhance iron absorption while mitigating adverse effects on gut microbiota.
The findings suggest that gut microbes and LPC are potential therapeutic targets for Alzheimer's disease.
Three-year collaboration to pioneer new insights in microbial sciences and health applications.
The interview with Björn O. Schröder from Umeå University explores groundbreaking research on the gut mucus layer, which shields intestinal tissues from bacterial invasion and inflammation.
New microbiome based therapy demonstrates safety and potential benefits for liver cirrhosis and mental health.
In the session's conclusion, CCNFSDU agreed to maintain the status quo for the next three to five years rather than start to work on new guidelines.
